scholarly journals Advances in Nanomaterials Used in Co-Delivery of siRNA and Small Molecule Drugs for Cancer Treatment

Nanomaterials ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 2467
Author(s):  
Shei Li Chung ◽  
Maxine Swee-Li Yee ◽  
Ling-Wei Hii ◽  
Wei-Meng Lim ◽  
Mui Yen Ho ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Small Molecule ◽  
Drug Carriers ◽  
Delivery Systems ◽  
Cancer Treatments ◽  
Small Molecule Drugs ◽  
Emerging Issues ◽  
Properties Of Materials ◽  
Interfering Rna ◽  
Novel Delivery Systems

Recent advancements in nanotechnology have improved our understanding of cancer treatment and allowed the opportunity to develop novel delivery systems for cancer therapy. The biological complexities of cancer and tumour micro-environments have been shown to be highly challenging when treated with a single therapeutic approach. Current co-delivery systems which involve delivering small molecule drugs and short-interfering RNA (siRNA) have demonstrated the potential of effective suppression of tumour growth. It is worth noting that a considerable number of studies have demonstrated the synergistic effect of co-delivery systems combining siRNA and small molecule drugs, with promising results when compared to single-drug approaches. This review focuses on the recent advances in co-delivery of siRNA and small molecule drugs. The co-delivery systems are categorized based on the material classes of drug carriers. We discuss the critical properties of materials that enable co-delivery of two distinct anti-tumour agents with different properties. Key examples of co-delivery of drug/siRNA from the recent literature are highlighted and discussed. We summarize the current and emerging issues in this rapidly changing field of research in biomaterials for cancer treatments.

scholarly journals Recent Advances of Nanotechnology-Facilitated Bacteria-Based Drug and Gene Delivery Systems for Cancer Treatment

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 940
Author(s):  
Chaojie Zhu ◽  
Zhiheng Ji ◽  
Junkai Ma ◽  
Zhijie Ding ◽  
Jie Shen ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Cancer Treatment ◽  
Delivery Systems ◽  
Cancer Targeting ◽  
Cancer Treatments ◽  
Recent Advances ◽  
Therapeutic Mechanisms ◽  
Bacterial Therapy ◽  
Targeting Ability ◽  
Drug And Gene Delivery

Cancer is one of the most devastating and ubiquitous human diseases. Conventional therapies like chemotherapy and radiotherapy are the most widely used cancer treatments. Despite the notable therapeutic improvements that these measures achieve, disappointing therapeutic outcome and cancer reoccurrence commonly following these therapies demonstrate the need for better alternatives. Among them, bacterial therapy has proven to be effective in its intrinsic cancer targeting ability and various therapeutic mechanisms that can be further bolstered by nanotechnology. In this review, we will discuss recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems in cancer treatment. Therapeutic mechanisms of these hybrid nanoformulations are highlighted to provide an up-to-date understanding of this emerging field.

scholarly journals Extracellular Vesicles as Natural Nanosized Delivery Systems for Small-Molecule Drugs and Genetic Material: Steps towards the Future Nanomedicines

2015 ◽  
Vol 18 (3) ◽  
pp. 396 ◽  
Author(s):  
Mustafa Kotmakçı ◽  
Vildan Bozok Çetintaş
Keyword(s):  
Extracellular Vesicles ◽  
Small Molecule ◽  
Protein Delivery ◽  
Drug Loading ◽  
Genetic Material ◽  
Delivery Systems ◽  
Small Molecule Drugs ◽  
The Common ◽  
Therapeutic Protocols ◽  
Targeting Ability

A new platform for drug, gene and peptide-protein delivery is emerging, under the common name of “extracellular vesicles”. Extracellular vesicles (EVs) are 30-1000 nm-sized cell-derived, liposome-like vesicles. Current research on EVs as nano-delivery systems for small-molecule drugs and genetic material, reveal that these tiny, biologically-derived vesicles carry a great potential to boost the efficacy of many therapeutic protocols. Several features of EVs; from efficacy to safety, from passive to active targeting ability, the opportunity to be biologically or chemically labelled, and most importantly, their eobiotic origin make them promising candidate for development of the next generation personalized nanomedicines. The aim of this article is to provide a view on the current research in which EVs are used as drug/genetic material delivery systems. Their application areas, drug loading and targeting strategies, and biodistribution properties are discussed.This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

scholarly journals Recent advances of curcumin and its analogues in breast cancer prevention and treatment

RSC Advances ◽  
2015 ◽  
Vol 5 (92) ◽  
pp. 75575-75588 ◽  
Author(s):  
Charlotta D. Mock ◽  
Brian C. Jordan ◽  
Chelliah Selvam
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Cancer Prevention ◽  
Breast Cancer Treatment ◽  
Delivery Systems ◽  
Breast Cancer Prevention ◽  
Curcumin Analogues ◽  
Prevention And Treatment ◽  
Recent Developments ◽  
Novel Delivery Systems

This review focuses on recent developments in the use of curcumin, curcumin analogues, and novel delivery systems as a preventive and therapeutic method for breast cancer treatment.

Self-assembling peptide-based nanodrug delivery systems

2019 ◽  
Vol 7 (12) ◽  
pp. 4888-4911 ◽  
Author(s):  
Qian Wang ◽  
Nan Jiang ◽  
Bo Fu ◽  
Fan Huang ◽  
Jianfeng Liu
Keyword(s):  
Drug Delivery ◽  
Small Molecule ◽  
Delivery Systems ◽  
Present Review ◽  
Peptide Conjugates ◽  
Nanodrug Delivery ◽  
Self Assembling ◽  
Small Molecule Drugs ◽  
Delivery Strategies

The present review outlines the methods designing self-assembling peptide-based NDDs for small molecule drugs, with an emphasis on the different drug delivery strategies and their applications in using peptides and peptide conjugates.

scholarly journals ImprovingIn VivoEfficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems

2017 ◽  
Vol 2017 ◽  
pp. 1-34 ◽  
Author(s):  
Lamia Mouhid ◽  
Marta Corzo-Martínez ◽  
Carlos Torres ◽  
Luis Vázquez ◽  
Guillermo Reglero ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Delivery Systems ◽  
Chemotherapeutic Agents ◽  
Bioactive Molecules ◽  
Antitumoral Activity ◽  
Cancer Treatments ◽  
Bioactive Ingredients ◽  
New Formulation

Cancer is among the leading causes of morbidity and mortality worldwide. Many of the chemotherapeutic agents used in cancer treatment exhibit cell toxicity and display teratogenic effect on nontumor cells. Therefore, the search for alternative compounds which are effective against tumor cells but reduce toxicity against nontumor ones is of great importance in the progress or development of cancer treatments. In this sense, scientific knowledge about relevant aspects of nutrition intimately involved in the development and progression of cancer progresses rapidly. Phytochemicals, considered as bioactive ingredients present in plant products, have shown promising effects as potential therapeutic/preventive agents on cancer in severalin vitroandin vivoassays. However, despite their bioactive properties, phytochemicals are still not commonly used in clinical practice due to several reasons, mainly attributed to their poor bioavailability. In this sense, new formulation strategies are proposed as carriers to improve their bioefficacy, highlighting the use of lipid-based delivery systems. Here, we review the potential antitumoral activity of the bioactive compounds derived from plants and the current studies carried out in animal and human models. Furthermore, their association with lipids as a formulation strategy to enhance their efficacyin vivois also reported. The development of high effective bioactive supplements for cancer treatment based on the improvement of their bioavailability goes through this association.

Effect of chemical composition and sulfated modification of alginate in the development of delivery systems based on electrostatic interactions for small molecule drugs

2020 ◽  
Vol 263 ◽  
pp. 127235 ◽  
Author(s):  
Zahra Nazemi ◽  
Mohammad Sadegh Nourbakhsh ◽  
Sahar Kiani ◽  
Hamed Daemi ◽  
Mohammad Kazemi Ashtiani ◽  
...  
Keyword(s):  
Chemical Composition ◽  
Small Molecule ◽  
Electrostatic Interactions ◽  
Delivery Systems ◽  
Small Molecule Drugs

scholarly journals Drug Transport across the Blood–Brain Barrier

2012 ◽  
Vol 32 (11) ◽  
pp. 1959-1972 ◽  
Author(s):  
William M Pardridge
Keyword(s):  
Blood Brain Barrier ◽  
Small Molecule ◽  
Drug Transport ◽  
Delivery Systems ◽  
Brain Barrier ◽  
Large Molecule ◽  
Transport Systems ◽  
Small Molecule Drugs ◽  
Blood Brain ◽  
The Brain

The blood–brain barrier (BBB) prevents the brain uptake of most pharmaceuticals. This property arises from the epithelial-like tight junctions within the brain capillary endothelium. The BBB is anatomically and functionally distinct from the blood–cerebrospinal fluid barrier at the choroid plexus. Certain small molecule drugs may cross the BBB via lipid-mediated free diffusion, providing the drug has a molecular weight <400 Da and forms <8 hydrogen bonds. These chemical properties are lacking in the majority of small molecule drugs, and all large molecule drugs. Nevertheless, drugs can be reengineered for BBB transport, based on the knowledge of the endogenous transport systems within the BBB. Small molecule drugs can be synthesized that access carrier-mediated transport (CMT) systems within the BBB. Large molecule drugs can be reengineered with molecular Trojan horse delivery systems to access receptor-mediated transport (RMT) systems within the BBB. Peptide and antisense radiopharmaceuticals are made brain-penetrating with the combined use of RMT-based delivery systems and avidin–biotin technology. Knowledge on the endogenous CMT and RMT systems expressed at the BBB enable new solutions to the problem of BBB drug transport.

Sign in / Sign up

Export Citation Format

Share Document